LifeMap Sciences, Tianjin Novogene & Shanghai Shanyi Announce Strategic Partnership to Offer Leading Clinical NGS Solution to...
January 10 2019 - 08:00AM
Business Wire
- Novogene Tianjin to offer end-to-end
sequencing through interpretation and reporting by integrating
LifeMap’s leading TGex Clinical NGS tertiary analysis platform with
their sequencing and bioinformatics services in China
- Partnership to expand LifeMap’s
access to the Chinese Market
LifeMap Sciences, Inc., a subsidiary of AgeX Therapeutics, Inc.
(NYSE American: AGE) announced today that Tianjin Novogene Medical
Laboratory, LifeMap, and Shanghai Shanyi today announced a
partnership to provide a combined, best-of-breed Clinical NGS
analysis and interpretation platform for Tianjin Novogene Medical
Laboratory’s customers in China.
LifeMap Sciences’ TGex is the leading provider of tertiary NGS
analysis and interpretation solutions for rare pediatric disorders
in the China market. It is today the clinical genetics solution of
choice for top tier pediatric and maternal hospitals, including
Peking Union Medical Center, Beijing Children’s Hospital, Shanghai
International Children’s Medical Center, Shenzhen Maternal Hospital
and Guanxi Maternal Hospital amongst others, as well as in private
labs. TGex is distributed in China by Shanghai Shanyi, which
provides molecular technologies, services and solutions throughout
the territory.
“We’re very excited about this partnership,” says Yaron Guan
Golan, Chief Executive Officer at LifeMap Sciences. “Novogene
Tianjin is a top tier provider of sequencing and bioinformatics
solutions in China and we are honored to have them select us to
provide TGex as part of their bioinformatics platform. The
partnership with Novogene Tianjin will allow us to rapidly expand
our offerings in the China market, and together to offer
best-of-breed end-to-end clinical NGS solutions to the China
market.”
“We’re proud to cooperate with Novogene and LifeMap,” said Lei
Li, GM at Shanghai Shanyi. “Both of them are top providers of
genomic services and solutions. The NGS interpretation marketing is
rapidly growing in China today as cost of sequencing decreases.
This cooperation between Novogene, LifeMap, and Shanghai Shanyi
will improve the quality of genetic diseases diagnosis and,
potentially, treatment throughout China.”
Questions regarding the above can be directed to Mr. Lei Li at
terry.lee@tgexsanyi.cn or to Yaron
Guan Golan, CEO at LifeMap Sciences, at yg@lifemapsc.com.
About Novogene Tianjin Medical Laboratory
Novogene Tianjin Medical Laboratory is a CAP accredited clinical
lab that provides high quality sequencing services to 1,920
scientific research institutes and universities, 720 hospitals, as
well as 1,430 pharmaceutical and agricultural laboratories.
For more information, visit https://en.novogene.com/.
About LifeMap Sciences
LifeMap Sciences is a life sciences technology company that
offers integrated, streamlined solutions that empower life
scientists worldwide to conduct cutting-edge basic, clinical and
applied biomedical research. LifeMap’s products are used in more
than 3,000 institutions including academia, research hospitals,
patent offices, and leading biopharma and diagnostic companies.
Operations worldwide are carried out from our offices in
California, Massachusetts, New Jersey, Tel Aviv, and Hong Kong.
LifeMap is a subsidiary of AgeX Therapeutics, Inc.
For more information, please visit
http://www.lifemapsc.com/.
About Shanghai Shanyi Biological technology
Shanghai Shanyi is a leading provider of molecular technology
service and solutions, including NGS interpretation, variant
validation services, DNA Extraction solutions, dedicated in
improving the molecular medical service quality in China.
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on
developing and commercializing innovative therapeutics for human
aging. Its PureStem® and UniverCyte™ manufacturing and
immunotolerance technologies are designed to work together to
generate highly defined, universal, allogeneic, off-the-shelf
pluripotent stem cell-derived young cells of any type for
application in a whole host of diseases with a high unmet medical
need. AgeX has two preclinical cell therapy programs: AGEX-VASC1
(vascular progenitor cells) for tissue ischemia and AGEX-BAT1
(brown fat cells) for Type II diabetes. AgeX’s revolutionary
longevity platform named induced Tissue Regeneration (iTR™) aims to
unlock cellular immortality and regenerative capacity to reverse
age-related changes within tissues. AGEX-iTR1547 is an iTR-based
formulation in preclinical development. HyStem® is AgeX’s delivery
technology to stably engraft PureStem cell therapies and slowly
release iTR molecules in the body. AgeX is aggressively developing
its core product pipeline for use in the clinic to extend human
healthspan, and is seeking opportunities to form licensing and
partnership agreements around its broad IP estate and proprietary
technology platforms for non-core clinical applications.
For more information, please visit www.agexinc.com or connect
with the company on Twitter, Facebook and YouTube.
Forward-Looking Statements
Certain statements contained in this release are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Any statements that are
not historical fact including, but not limited to statements that
contain words such as “will,” “believes,” “plans,” “anticipates,”
“expects,” “estimates” should also be considered forward-looking
statements. Forward-looking statements involve risks and
uncertainties. Actual results may differ materially from the
results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that
affect the business of AgeX Therapeutics, Inc. and its
subsidiaries, particularly those mentioned in the cautionary
statements found in more detail in the “Risk Factors” section of
AgeX’s Information Statement filed as an exhibit to its
Registration Statement on Form 10 with the Securities and Exchange
Commissions (copies of which may be obtained at www.sec.gov).
Subsequent events and developments may cause these forward-looking
statements to change. AgeX specifically disclaims any obligation or
intention to update or revise these forward-looking statements as a
result of changed events or circumstances that occur after the date
of this release, except as required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190110005267/en/
Media Contact for AgeX:Bill DouglassGotham Communications,
LLCbill@gothamcomm.com(646) 504-0890
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Feb 2024 to Mar 2024
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Mar 2023 to Mar 2024